KAWAMOTO RICHARD MASARU,WARSHAKOON NAMAL CHITHRANGA,GREIS KENNETH DONALD,BOYER ANGELIQUE SUN,WU SHENGDE,EDOKIMOV ARTEM G.
申请号：
NZ60173107
公开号：
NZ601731A
申请日:
2007.06.26
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
601731 Disclosed are { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} -acetic acid derivatives as represented by the general formula, as inhibitors of human protein prolyl hydroxylase for stimulating an angiogenic response for increasing blood flow, oxygen delivery and energy utilization in ischemic tissues； wherein the specific compounds of formula (I) are chosen from { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid methyl ester, [(3-hydroxy-5-(4-methylphenyl)pyridine-2-carbonyl)amino]acetic acid, { [5-(2-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid methyl ester, { [5-(4-cyanophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, { [5-(4-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, { [5-(2-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid and 5-(3-chlorophenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide； or a pharmaceutically acceptable salt thereof. Further disclosed is a composition comprising one or more compounds as defined above, or a pharmaceutically acceptable salt thereof； and one or more excipients or carriers； for treating a disease selected from diabetic retinopathy, macular degeneration, sickle cell anemia, sarcoid, syphilis, pseudoxanthoma elasticum, Paget&rsquo；s disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme&rsquo；s disease, systemic lupus erythematosis, retinopathy of prematurity, Eales&rsquo； disease, Behcet&rsquo；s disease, infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Best&rsquo；s disease, myopia, optic pits, Stargardt&rsquo；s disease, pars planitis, chronic retinal detachment, hyperviscosity syndrome, toxoplasmosis, trauma post-laser complications, diseases associated with rubeosis, and proliferative vitroeretinopathy, Crohn&rsquo；s disease and ulcerative colitis, psoria
